Answers are grounded in this paper and cite their sources.
The human uricase (UOX) gene was pseudogenized during evolution, leaving uric acid as the terminal product of purine metabolism. Heterologous uricases can elicit anti-drug antibodies, which limit their long-term use. Here, we restored activity to a human-pseudogene-derived uricase reference through molecular-evolution-guided rational design. Sequence alignment guided the construction of reversion mutants by overlap-extension PCR and two rounds of combinatorial optimization. Structural modeling and an accelerated co-culture dendritic cell (acDC) assay were used to generate mechanistic hypotheses and compare cytokine responses. Reconstructed activity first appeared in H4 and peaked in H7 (2.03 U/mg). H2-EL, carrying eight substitutions, reached 4.1 U/mg, and the second-round mutant H7-5, with fifteen substitutions, reached 7.14 U/mg. Structural modeling suggested contributions from intra-subunit stabilization, interfacial assembly, active-site modulation, and long-range coupling. Both H7-5 and H2-EL elicited significantly weaker acDC cytokine responses than Aspergillus flavus uricase. H2-EL induced only a marginal IFN-γ elevation above background, whereas IL-2 remained at the negative-control level. Thus, H2-EL combines high catalytic activity with attenuated acDC cytokine responses and a reduced set of eight substitutions. Its clinical immunogenicity remains to be established.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: